Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough Diagnostic Platform to Rapidly Detect Life-Threatening Bloodstream Infections

By LabMedica International staff writers
Posted on 30 Sep 2025

Yeast bloodstream infections affect more than 30,000 patients in the U. More...

S. each year and are associated with mortality rates exceeding 40%. Survival depends on rapid antifungal treatment, yet the current diagnostic gold standard, blood culture, requires one to five days. This delay can be fatal, highlighting the urgent need for faster, more reliable diagnostic tools to detect life-threatening infections at an earlier stage. Now, a breakthrough diagnostic platform could enable rapid testing for life-threatening bloodstream infections.

Scanogen (Baltimore, MD, USA) has developed an automated diagnostic platform powered by its proprietary Single Molecule and Rapid Tethering (SMART) technology. SMART is a revolutionary platform technology for ultra-sensitive and rapid detection of nucleic acids and microorganisms in body fluids. SMART technology unlocks entirely new diagnostic possibilities by enabling direct detection of nucleic acids without the need for amplification.

Scanogen automated diagnostic system is designed to deliver results directly from whole blood within two hours, eliminating the need for blood culture. Featuring a compact desktop instrument and disposable cartridge system, the platform offers a simplified workflow that ensures quick and accurate pathogen detection.

In recent validation studies, the platform demonstrated 96% sensitivity and 99% specificity. Importantly, it was also able to detect Candida auris, a pathogen classified as an urgent public health threat. These performance metrics underscore the system’s potential to significantly improve diagnostic speed and accuracy for fungal bloodstream infections. With timely pathogen identification, physicians can quickly initiate targeted antimicrobial therapy.

With support from a USD 2.9 million NIH Commercialization Readiness Pilot Program grant, funded by the National Institute of Allergy and Infectious Diseases (NIAID), Scanogen will focus on scaling reagent and cartridge production under FDA-compliant processes. The funding accelerates the pathway from laboratory development to widespread clinical adoption. Additional work will strengthen the software with cybersecurity and LIS integration while transferring the system into production.

These steps will position the company to launch pivotal clinical studies for regulatory clearance. Going forward, the technology has the potential to transform the standard of care for bloodstream infections by enabling earlier treatment and reducing mortality. Hospitals could integrate the system into existing diagnostic workflows, providing a practical, rapid-response solution to an urgent global health challenge.

“This funding is a major step toward bringing our rapid test to hospitals. Faster diagnosis means earlier treatment—and more lives saved,” said Dr. Al Celedon, Founder and CEO of Scanogen. “The new funding accelerates the pathway from laboratory development to widespread clinical adoption.”

Related Links:
Scanogen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.